HLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population

Annals of Occupational and Environmental Medicine

Xiang Gao¹  Lei Han¹  Lan Yuan²  Yongchen Yang⁴  Guimei Gou⁴  Hengjuan Sun⁴  Ling Lu¹  Liming Bao³ 

[1] Departments of Rheumatology and Occupational Medicine, Huashan Hospital of Fudan University, Shanghai, China

[2] Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, Children’s Hospital of Chongqing Medical University, Chongqing, China

[3] Department of Pathology, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire, USA

[4] Shanghai Children’s Hospital, Shanghai Children’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

关键词: Chinese;    Susceptibility;    HLA;    Dermatomyositis;    Polymyositis;   

Others  :  814035
DOI  :  10.1186/1471-5945-14-9

 received in 2013-11-18, accepted in 2014-05-28,  发布年份 2014

【 摘 要 】

Background

Polymyositis (PM) and dermatomyositis (DM) are idiopathic inflammatory myopathies. Genetic variability in human leukocyte antigen (HLA) genes plays an important role in the pathogenesis of PM and DM. However, few studies on the subject in Chinese populations have been reported thus far.

Methods

We studied the influence of HLA polymorphisms on DM and PM susceptibility by analyzing HLA-DRB1, HLA-DQA1, and HLA-DQB1 alleles in 71 adult DM patients, 20 adult PM patients, and 113 controls in a Han Chinese population.

Results

A positive association was found between HLA-DQA1*0104 and DM (p = 0.01; corrected p (p_corr) NS; odds ratio (OR) = 2.58; 95% confidence interval (CI): 1.18–5.64), while an inverse correlation was noted between HLA-DQB1*0303 and myositis patients with interstitial lung inflammation (p = 0.01; p_corr NS; OR = 0.25; 95% CI: 0.07–0.73). A positive relationship was also observed between HLA-DRB1*07 and DM (p = 0.01; p_corr NS; OR = 2.26; 95% CI: 1.12–4.59), while HLA-DRB1*03 seems to be protective against DM (p = 0.01; p_corr NS; OR = 0.26; 95% CI: 0.06–0.81). The lung complication was closely associated with HLA-DRB1*04 (p = 0.01; p_corr NS; OR = 2.82; 95% CI: 1.15–6.76) and HLA-DRB1*12 (p = 0.02; p_corr NS; OR = 2.52; 95% CI: 1.02–6.07). The frequency of HLA-DRB1*07 was significantly higher among myositis patients with dysphagia than among controls (p = 0.01; p_corr NS; OR = 4.78; 95% CI: 1.03–24.42). The putative haplotype DRB1*07-DQA1*01-DQB1*02 was positively correlated with DM (p = 0.03; p_corr NS; OR = 2.90; 95% CI: 1.02–8.93) and the lung complication (p = 0.02; p_corr NS; OR = 3.45; 95% CI: 1.04–11.58).

Conclusions

Our results demonstrate that HLA alleles may be involved in susceptibility to adult DM and PM in the Han Chinese population.

【 授权许可】

   
2014 Gao et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mammen AL: Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010, 1184:134-153.
• [2]Luppi P, Rossiello MR, Faas S, Trucco M: Genetic background and environment contribute synergistically to the onset of autoimmune diseases. J Mol Med (Berl) 1995, 73(8):381-393.
• [3]Thorsby E, Lie BA: HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transpl Immunol 2005, 14(3–4):175-182.
• [4]O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Rider LG, Chanock SJ, Foster CB, Bunch T, Blackshear PJ, Plotz PH, Love LA, Miller FW: Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006, 85(2):111-127.
• [5]Seldin MF, Amos CI, Ward R, Gregersen PK: The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum 1999, 42(6):1071-1079.
• [6]McLeod R, Buschman E, Arbuckle LD, Skamene E: Immunogenetics in the analysis of resistance to intracellular pathogens. Curr Opin Immunol 1995, 7(4):539-552.
• [7]Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD: Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996, 39(9):1507-1518.
• [8]Reed AM, Pachman LM, Hayford J, Ober C: Immunogenetic studies in families of children with juvenile dermatomyositis. J Rheumatol 1998, 25(5):1000-1002.
• [9]Furuya T, Hakoda M, Higami K, Ueda H, Tsuchiya N, Tokunaga K, Kamatani N, Kashiwazaki S: Association of HLA class I and class II alleles with myositis in Japanese patients. J Rheumatol 1998, 25(6):1109-1114.
• [10]Han X, Zhai N, Zhang Y, LI J, Liu J, Song F, Cehn H: Association of HLA-DRB1 alleles and polymyositis/dermatomyositis in northen Chinese. Chin J Microbiol Immunol 2003, 23(3):225-227.
• [11]Han X, Zhai N, Zhang Q, Li J, Liu J, Du J, Song F: Association of HLA-DQB1 alleles and dermatomyositis/ polymyositis. Chin J Med Genet 2002, 19(4):322-323.
• [12]Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292(8):403-407.
• [13]Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292(7):344-347.
• [14]Olerup O, Aldener A, Fogdell A: HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993, 41(3):119-134.
• [15]Olerup O, Zetterquist H: HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992, 39(5):225-235.
• [16]Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68(4):978-989.
• [17]Engel AG, Arahata K, Emslie-Smith A: Immune effector mechanisms in inflammatory myopathies. Res Publ Assoc Res Nerv Ment Dis 1990, 68:141-157.
• [18]Robinson AB, Reed AM: Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011, 7(11):664-675.
• [19]Shamim EA, Rider LG, Pandey JP, O'Hanlon TP, Jara LJ, Samayoa EA, Burgos-Vargas R, Vazquez-Mellado J, Alcocer-Varela J, Salazar-Paramo M, Kutzbach AG, Malley JD, Targoff IN, Garcia-De la Torre I, Miller FW: Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002, 46(7):1885-1893.
• [20]Chinoy H, Salway F, Fertig N, Oddis CV, Ollier WE, Cooper RG: Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. Rheumatology (Oxford) 2009, 48(5):591-592.
• [21]Marie I, Hachulla E, Levesque H, Reumont G, Ducrotte P, Cailleux N, Hatron PY, Devulder B, Courtois H: Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol 1999, 26(12):2706-2709.
• [22]O'Hanlon TP, Rider LG, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW: HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 2006, 54(11):3670-3681.
• [23]Yu KH, Wu YJ, Kuo CF, See LC, Shen YM, Chang HC, Luo SF, Ho HH, Chen IJ: Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 2011, 30(12):1595-1601.
• [24]Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, Luo SF: Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 2011, 165(6):1273-1279.
• [25]Chinoy H, Lamb JA, Ollier WE, Cooper RG: Recent advances in the immunogenetics of idiopathic inflammatory myopathy. Arthritis Res Ther 2011, 13(3):216. BioMed Central Full Text
• [26]Furuya T, Hakoda M, Tsuchiya N, Kotake S, Ichikawa N, Nanke Y, Nakajima A, Takeuchi M, Nishinarita M, Kondo H, Kawasaki A, Kobayashi S, Mimori T, Tokunaga K, Kamatani N: Immunogenetic features in 120 Japanese patients with idiopathic inflammatory myopathy. J Rheumatol 2004, 31(9):1768-1774.
• [27]Rider LG, Shamim E, Okada S, Pandey JP, Targoff IN, O'Hanlon TP, Kim HA, Lim YS, Han H, Song YW, Miller FW: Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999, 42(6):1285-1290.
• [28]Chinoy H, Salway F, Fertig N, Shephard N, Tait BD, Thomson W, Isenberg DA, Oddis CV, Silman AJ, Ollier WE, Cooper RG: In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006, 8(1):R13. BioMed Central Full Text
• [29]Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70(6):360-374.
• [30]Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, Jablonska S: Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40(7):1257-1266.
• [31]Feldman BM, Rider LG, Reed AM, Pachman LM: Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371(9631):2201-2212.